Aviragen Therapeutics (AVIR) Tops Q2 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.34), $0.13 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Gordon Haskett cuts TJX Companies rating to Accumulate